electroCore Inc. (ECOR)
6.82
0.37 (5.74%)
At close: Mar 31, 2025, 12:19 PM
Company Description
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies.
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years.
The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
electroCore Inc.

Country | United States |
IPO Date | Jun 22, 2018 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 73 |
CEO | Daniel S. Goldberger |
Contact Details
Address: 200 Forge Way Rockaway, New Jersey United States | |
Website | https://www.electrocore.com |
Stock Details
Ticker Symbol | ECOR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001560258 |
CUSIP Number | 28531P103 |
ISIN Number | US28531P2020 |
Employer ID | 20-3454976 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Daniel S. Goldberger | Chief Executive Officer & Director |
Joshua S. Lev | Chief Financial Officer |
Brian M. Posner CPA, MBA. | Consultant |
Carrie Kochek | Senior Director of Human Resources |
Donald Melnikoff | Senior Vice President of Engineering, Regulatory & Compliance |
Dr. Peter S. Staats M.B.A., M.D. | Chief Medical Officer |
Dr. Thomas J. Errico M.D. | Founder & Independent Director |
Manuel A. Marques | Senior Vice President of Operations |
Michael Mansfield | Vice President of Marketing |
Mitch Deshon | Vice President of Global Sales & Business Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Mar 18, 2025 | 4 | Filing |
Mar 17, 2025 | 4 | Filing |
Mar 12, 2025 | S-8 | Filing |
Mar 12, 2025 | 10-K | Annual Report |
Mar 12, 2025 | 8-K | Current Report |
Mar 05, 2025 | 4 | Filing |
Feb 28, 2025 | 8-K | Current Report |
Jan 31, 2025 | S-3/A | [Amend] Filing |
Jan 24, 2025 | S-3 | Filing |